Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Sets INNOVENT BIO's TP at HKD111; Strategic Partnership with Eli Lilly A Positive Surprise
Recommend 4 Positive 7 Negative 8 |
||||
|
||||
|
INNOVENT BIO (01801.HK) has entered into a strategic partnership with Eli Lilly and Company (LLY.US) to jointly develop new biological drugs focused on oncology and immunology on a global scale, according to a report from JPMorgan. JPMorgan considered this collaboration a positive surprise, as it not only marked another crucial milestone in INNOVENT BIO's journey towards becoming a global biopharmaceutical company but also highlighted the strength of the company's R&D platform. Reiterating INNOVENT BIO as one of its top picks among Chinese biotech companies under its coverage, JPMorgan gave INNOVENT BIO an Overweight rating and a target price of HKD111. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
